Roswell Park Cancer Institute (RPCI) is an independent, free-standing research, education and clinical cancer care Institute. Dr. Donald Trump, CCSG PI and RPCI President/CEO, is responsible solely to the RPCI Board of Directors. RPCI has been continuously recognized as a Cancer Center since NCI first designated centers in 1974 and has been designated as a comprehensive center since that term was first employed. This application requests continued NCI support for another five years. RPCI occupies a 27 acre campus near downtown Buffalo. The RPCI campus consists of 1.6 million square feet (sf) of laboratory, office, clinical and education. An additional 142,000 sf clinical care, clinical research and office building began construction on April 18, 2013. New developments on the main campus since last review have included opening of the Centers for Immunotherapy, Robotic Surgery, and Personalized Medicine. An additional 16,000 sf of clinical space have been opened at three affiliate sites. While the population of the RPCI catchment area (the 8 county region of WNY from which ~86% of RPCI patients are drawn) has been generally stable at ~1.5M, the number of tumor registry cases has increased 25% since 2008. In 2012 RPCI physicians cared for 4,242 new tumor registry cases and a total of 8,626 new analytic and non-analytic cases. Since the last competitive renewal in 2008, RPCI has continued scientific, clinical, population science and education program growth, despite a difficult economic environment. This growth is demonstrated by: 1) recruitment of 137 new faculty clinicians and researchers, of which 51 are new CCSG members;2) a 17% increase in total peer-reviewed funding from 2008 to 2013;3) an increase in high-impact (impact factor>10) publications (91 to 193);4) increased accrual to first-in-human, phase I, investigator-initiated studies;24 accruals in 2008 vs 118 in 2012 and the highest phase I trial institutional recruitment in RPCI history;5) 2.5X increase in the number of therapeutic (treatment) trials supported by peer-reviewed funding (27 to 67);and 6) opening of three new satellite RPCI facilities. RPCI has expanded its educational programs, including an international program for the training of cancer scientists, clinicians and administrators from around the world. RPCI has successfully recruited three Senior Leaders, and invested $277 million in resources for the future to build on RPCI's unique opportunities in experimental therapeutics, translational medicine, genomics and education.

Public Health Relevance

Roswell Park Cancer Institute is a multidisciplinary, translational Comprehensive Cancer Center, with a mission to understand, prevent and cure cancer. RPCI utilizes CCSG support to build on unique strengths and opportunities, moving laboratory science into advanced treatment, prevention, diagnosis, and education.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-37S4
Application #
8923555
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$150,000
Indirect Cost
$64,530
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786
Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527
Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93
Shenoy, Gautam N; Loyall, Jenni; Maguire, Orla et al. (2018) Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 6:236-247

Showing the most recent 10 out of 1555 publications